ILC2

City of Hope Research Reveals an Immune Cell That Can Attack Cancer

Retrieved on: 
星期三, 一月 10, 2024

According to preclinical research published online today in Cell , one of the world’s premier scientific journals, researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.

Key Points: 
  • According to preclinical research published online today in Cell , one of the world’s premier scientific journals, researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.
  • View the full release here: https://www.businesswire.com/news/home/20240109475331/en/
    City of Hope researchers discovered that ILC2s, pictured here, can attack cancer cells.
  • However in the highly translational labs at City of Hope, researchers prioritized the examination of human cells and found that human ILC2s do not work the same as mouse ILC2s.
  • In fact, Yu is founding director of the Natural Killer Cell Biology Research Program at City of Hope, a national leader in the field.

SinoMab's IND Application of SM17 has once again Received Approval from NAMP

Retrieved on: 
星期二, 九月 12, 2023

Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and patient's quality of life.

Key Points: 
  • Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and patient's quality of life.
  • The Company actively promoted the indication research of SM17, laying a foundation for subsequent proof of concept and commercialization.
  • The IND application of SM17 for AD has been approved by the NMPA, which fully reflects the recognition of the differentiated advantages of SM17 in the field of AD and has a bright future.
  • Currently, SM17 has obtained IND approvals from the NMPA for the treatment of asthma and AD, while our Phase I study for SM17 conducted in the US is near completion.

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP

Retrieved on: 
星期一, 八月 14, 2023

IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of multiple airway viral responses and allergic diseases, such as asthma.

Key Points: 
  • IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of multiple airway viral responses and allergic diseases, such as asthma.
  • Meanwhile, the Company is also advancing the Phase I clinical study of SM17 in the U.S. at full speed.
  • The potential first-in-target antibody of SM17 has demonstrated the potential efficacy for multiple indications, including asthma and IPF (Idiopathic Pulmonary Fibrosis).
  • Compared with other currently approved therapeutic antibody drugs targeting ILC2s downstream pathway, SM17 has a differentiated advantage at the source.

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

Retrieved on: 
星期一, 五月 22, 2023

The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

Key Points: 
  • The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.
  • Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent.
  • The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.
  • It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients.

SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

Retrieved on: 
星期一, 五月 22, 2023

The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

Key Points: 
  • The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.
  • Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent.
  • The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.
  • It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients.

Foundery Innovations Establishes Scientific Advisory Board with Appointment of Key Opinion Leaders in Immunology and Oncology

Retrieved on: 
星期二, 三月 28, 2023

SAN FRANCISCO, March 28, 2023 (GLOBE NEWSWIRE) -- Foundery Innovations (“Foundery”), a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced the establishment of its scientific advisory board (“SAB”) with the appointments of key opinion leaders (“KOLs”) in immunology, oncology, and protein engineering.

Key Points: 
  • SAN FRANCISCO, March 28, 2023 (GLOBE NEWSWIRE) -- Foundery Innovations (“Foundery”), a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced the establishment of its scientific advisory board (“SAB”) with the appointments of key opinion leaders (“KOLs”) in immunology, oncology, and protein engineering.
  • Dr. Locksley’s laboratory pioneered the use of mice genetically engineered to express cytokines during allergic immune responses.
  • Foundery is in discussions with a handful of other KOLs and looks forward to announcing them in the coming months.
  • Additionally, Foundery’s scientific advisor pool is expected to grow in parallel with the Company’s portfolio expansion.

Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma

Retrieved on: 
星期二, 八月 9, 2022

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the initiation of a Phase 1b multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the initiation of a Phase 1b multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient.
  • TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory diseases.
  • The Upstream team is excited to bring UPB-101 to asthma study participants.
  • Advancing UPB-101 to a multiple ascending dose trial in asthma patients marks a key milestone for our team.

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

Retrieved on: 
星期三, 六月 15, 2022

SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom).

Key Points: 
  • SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom).
  • Despite the pandemic, SinoMab have soon initiated the first-in-human dose in the Phase I clinical trial.
  • After evaluating and choosing the lead candidate, it was licensed to SinoMab to take forward into clinical development and towards patients.
  • Following our flagship product, SM03 and key product, SN1011, we now have another key asset entering the clinical trial stage.

Global Asthma Pipeline Market Research Report 2022: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
星期四, 三月 10, 2022

The publisher's, "Asthma - Pipeline Insight, 2022," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Asthma pipeline landscape.

Key Points: 
  • The publisher's, "Asthma - Pipeline Insight, 2022," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Asthma pipeline landscape.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D.
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Asthma therapeutics?